Bank of America
NGEN

Bank of America’s NervGen Pharma NGEN Stock Holding History

Bank of America’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$756K Buy
+200,656
New +$869K ﹤0.01% 4667

Other funds holding NGEN

PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
VFIC
Valley Forge Investment Consultants Audubon, Pennsylvania $334M AUM 17.84% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

Bank of America's NGEN Position: Q1 2026 in Review

Bank of America opened a new position in NervGen Pharma (NGEN) in Q1 2026: 200,656 shares worth $756K. The stake represents ﹤0.01% of the portfolio and ranks #4667 among its holdings.

45 funds tracked by Wall St. Rank hold NGEN as of Q1 2026.

  • Bank of America held 200,656 shares of NervGen Pharma worth $756K as of Q1 2026.
  • NervGen Pharma was a new Bank of America position in Q1 2026.
  • NervGen Pharma made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4667 holding.
  • 45 funds tracked by Wall St. Rank held NervGen Pharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.